Xin Lang Cai Jing·2026-02-10 02:50Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable increase in financing and a high level of margin trading, indicating investor interest and potential volatility in the stock [1][2]. Group 2 - On February 9, Junshi Biosciences' stock rose by 1.43%, with a trading volume of 261 million yuan. The financing buy-in amount for the day was 22.56 million yuan, while the financing repayment was 28.16 million yuan, resulting in a net financing outflow of 5.61 million yuan [1]. - As of February 9, the total margin trading balance for Junshi Biosciences was 1.448 billion yuan, with the financing balance accounting for 5.30% of the circulating market value, which is above the 90th percentile of the past year [1]. - In terms of short selling, on February 9, Junshi Biosciences had 700 shares repaid and 7,100 shares sold short, amounting to 251,300 yuan at the closing price. The remaining short selling volume was 306,300 shares, with a short selling balance of 10.84 million yuan, also above the 60th percentile of the past year [1]. - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2]. - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2]. - As of September 30, 2025, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per shareholder, a decrease of 12.96% [2]. - Among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period, while Huaxia's Science and Technology Innovation Board 50 ETF held 18.97 million shares, a decrease of 1.07 million shares [2].